Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1

BACKGROUND: Low-grade gliomas (LGGs) occurring in children can result in many different neurologic complications, including seizures. MEK inhibitors are increasingly being used to treat LGG, but their effect on associated neurologic symptoms has not been established. RESULTS: Here, we report a patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantor, Evan, Meyer, Ashley, Morris, Stephanie M., Weisenberg, Judith L. Z., Brossier, Nicole M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617819/
https://www.ncbi.nlm.nih.gov/pubmed/35648241
http://dx.doi.org/10.1007/s00381-022-05571-y
_version_ 1784820917084356608
author Cantor, Evan
Meyer, Ashley
Morris, Stephanie M.
Weisenberg, Judith L. Z.
Brossier, Nicole M.
author_facet Cantor, Evan
Meyer, Ashley
Morris, Stephanie M.
Weisenberg, Judith L. Z.
Brossier, Nicole M.
author_sort Cantor, Evan
collection PubMed
description BACKGROUND: Low-grade gliomas (LGGs) occurring in children can result in many different neurologic complications, including seizures. MEK inhibitors are increasingly being used to treat LGG, but their effect on associated neurologic symptoms has not been established. RESULTS: Here, we report a patient with neurofibromatosis type 1 (NF1), medically refractory epilepsy (MRE), and an extensive optic pathway glioma (OPG) who developed dose-dependent seizure control while being treated with selumetinib. Seizure frequency rebounded after dose reduction for cardiac toxicity, then improved, and finally ceased after restarting full dosing, allowing confidence in the cause of improvement. CONCLUSION: Selumetinib may have promise in epilepsy management in other children with NF1 or LGG.
format Online
Article
Text
id pubmed-9617819
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-96178192022-10-31 Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1 Cantor, Evan Meyer, Ashley Morris, Stephanie M. Weisenberg, Judith L. Z. Brossier, Nicole M. Childs Nerv Syst Case Report BACKGROUND: Low-grade gliomas (LGGs) occurring in children can result in many different neurologic complications, including seizures. MEK inhibitors are increasingly being used to treat LGG, but their effect on associated neurologic symptoms has not been established. RESULTS: Here, we report a patient with neurofibromatosis type 1 (NF1), medically refractory epilepsy (MRE), and an extensive optic pathway glioma (OPG) who developed dose-dependent seizure control while being treated with selumetinib. Seizure frequency rebounded after dose reduction for cardiac toxicity, then improved, and finally ceased after restarting full dosing, allowing confidence in the cause of improvement. CONCLUSION: Selumetinib may have promise in epilepsy management in other children with NF1 or LGG. Springer Berlin Heidelberg 2022-06-01 2022 /pmc/articles/PMC9617819/ /pubmed/35648241 http://dx.doi.org/10.1007/s00381-022-05571-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Case Report
Cantor, Evan
Meyer, Ashley
Morris, Stephanie M.
Weisenberg, Judith L. Z.
Brossier, Nicole M.
Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1
title Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1
title_full Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1
title_fullStr Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1
title_full_unstemmed Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1
title_short Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1
title_sort dose-dependent seizure control with mek inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617819/
https://www.ncbi.nlm.nih.gov/pubmed/35648241
http://dx.doi.org/10.1007/s00381-022-05571-y
work_keys_str_mv AT cantorevan dosedependentseizurecontrolwithmekinhibitortherapyforprogressivegliomainachildwithneurofibromatosistype1
AT meyerashley dosedependentseizurecontrolwithmekinhibitortherapyforprogressivegliomainachildwithneurofibromatosistype1
AT morrisstephaniem dosedependentseizurecontrolwithmekinhibitortherapyforprogressivegliomainachildwithneurofibromatosistype1
AT weisenbergjudithlz dosedependentseizurecontrolwithmekinhibitortherapyforprogressivegliomainachildwithneurofibromatosistype1
AT brossiernicolem dosedependentseizurecontrolwithmekinhibitortherapyforprogressivegliomainachildwithneurofibromatosistype1

Ejemplares similares